Last reviewed · How we verify
Accelerated 1 hour-infusion
The drug, an accelerated 1-hour infusion, is currently marketed by Asan Medical Center. A key strength is the protection of its core composition, which is secured until the key patent expiry in 2028. The primary risk lies in the lack of disclosed primary indication and revenue data, which may limit strategic planning and market positioning.
At a glance
| Generic name | Accelerated 1 hour-infusion |
|---|---|
| Also known as | Infliximab (Remicade, Centocor, Malvern, Philadelphia, PA) |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (PHASE1)
- uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies (PHASE1)
- Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction (PHASE4)
- Immunosurveillance for Metastatic Colorectal Cancer (PHASE1, PHASE2)
- Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer (PHASE1, PHASE2)
- Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor (PHASE1)
- A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Accelerated 1 hour-infusion CI brief — competitive landscape report
- Accelerated 1 hour-infusion updates RSS · CI watch RSS
- Asan Medical Center portfolio CI